Importance Parkinson disease is the second most common neurodegenerative disease
worldwide. Although no available therapies alter the underlying neurodegenerative process …

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many
as 1–2% of persons aged 60 years and older. With the aging of the population, the …

Levodopa is the most effective medication for the treatment of the motor symptoms of
Parkinson's disease. However, over time, the clinical response to levodopa becomes …

Background: Recent short-term studies suggested that amantadine (Ama) might ameliorate
dyskinesia in patients with Parkinson's disease. A double-blind study programmed over 12 …

Levodopa treatment remains the gold standard for Parkinson's disease, but shortcomings
related to the pharmacological profile, notably, oral administration and the consequent …

Abstract Blood-Brain Barrier (BBB) acts as a highly impermeable barrier, presenting an
impediment to the crossing of most classical drugs targeted for neurodegenerative diseases …

Schizophrenia is a highly heritable, chronic, severe, disabling neurodevelopmental brain
disorder with a heterogeneous genetic and neurobiological background, which is still poorly …

Purpose Tolcapone is an efficacious catechol-O-methyltransferase inhibitor for Parkinson's
disease (PD). However, safety issues hampered its use in clinical practice. We aimed to …

Dieses Buch vermittelt einen kompetenten und fächerübergreifenden Überblick über das
aktuelle Wissen auf dem Gebiet der Parkinson-Krankheit. Es ist im deutschsprachigen …

Visual hallucinations (VH) are commonly found in the course of synucleinopathies like
Parkinson's disease and dementia with Lewy bodies. The incidence of VH in these …